Clinical Trials
18
Active:0
Completed:14
Trial Phases
4 Phases
Phase 1:3
Phase 2:8
Phase 3:6
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (18 trials with phase data)• Click on a phase to view related trials
Phase 2
8 (44.4%)Phase 3
6 (33.3%)Phase 1
3 (16.7%)Phase 4
1 (5.6%)Study to Evaluate the Effect of Naltrexone and Bupropion Combination on the Pharmacokinetics of Metformin in Healthy Participants
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Orexigen Therapeutics, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT02745912
Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants
Phase 1
Completed
- Conditions
- Heart Repolarization
- Interventions
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2016-11-01
- Lead Sponsor
- Orexigen Therapeutics, Inc
- Target Recruit Count
- 84
- Registration Number
- NCT02735603
Naltrexone/Bupropion Cardiovascular Outcomes Study
Phase 4
Terminated
- Conditions
- ObesityCardiovascular Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Orexigen Therapeutics, Inc
- Target Recruit Count
- 67
- Registration Number
- NCT02638129
Bioequivalence Study Comparing Naltrexone SR/Bupropion SR Trilayer Tablets From Two Manufacturers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)Drug: Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
- First Posted Date
- 2014-10-08
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Orexigen Therapeutics, Inc
- Target Recruit Count
- 80
- Registration Number
- NCT02259179
- Locations
- 🇺🇸
Quintiles Phase One Services, LLC, Overland Park, Kansas, United States
Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/ Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects
Phase 3
Completed
- Conditions
- ObesityOverweight
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Orexigen Therapeutics, Inc
- Target Recruit Count
- 242
- Registration Number
- NCT01764386
- Locations
- 🇺🇸
Radiant Research, Anderson, South Carolina, United States
🇺🇸Radiant Research, Inc., Columbus, Ohio, United States
🇺🇸PMG Research of Raleigh, Raleigh, North Carolina, United States
- Prev
- 1
- 2
- 3
- 4
- Next
News
No news found